Jason N. Butler
Stock Analyst at Citizens
(2.54)
# 2,404
Out of 5,045 analysts
9
Total ratings
71.43%
Success rate
10.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason N. Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WULF TeraWulf | Maintains: Market Outperform | $18 → $22 | $15.22 | +44.55% | 1 | Oct 29, 2025 | |
| RZLT Rezolute | Maintains: Market Outperform | $9 → $17 | $9.75 | +74.36% | 1 | Oct 29, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $95 → $114 | $104.01 | +9.60% | 1 | Sep 25, 2025 | |
| CRMD CorMedix | Reiterates: Market Outperform | $22 | $11.63 | +89.25% | 1 | Sep 9, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $62.61 | +24.58% | 1 | Sep 2, 2025 | |
| PGEN Precigen | Maintains: Market Outperform | $6 → $8 | $4.01 | +99.50% | 1 | Aug 19, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $19 → $18 | $10.21 | +76.30% | 1 | Aug 13, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Market Outperform | $30 → $35 | $22.66 | +54.46% | 1 | Aug 7, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $78 | $64.55 | +20.84% | 1 | Aug 6, 2025 |
TeraWulf
Oct 29, 2025
Maintains: Market Outperform
Price Target: $18 → $22
Current: $15.22
Upside: +44.55%
Rezolute
Oct 29, 2025
Maintains: Market Outperform
Price Target: $9 → $17
Current: $9.75
Upside: +74.36%
ABIVAX Société Anonyme
Sep 25, 2025
Maintains: Market Outperform
Price Target: $95 → $114
Current: $104.01
Upside: +9.60%
CorMedix
Sep 9, 2025
Reiterates: Market Outperform
Price Target: $22
Current: $11.63
Upside: +89.25%
Cytokinetics
Sep 2, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $62.61
Upside: +24.58%
Precigen
Aug 19, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.01
Upside: +99.50%
Zevra Therapeutics
Aug 13, 2025
Maintains: Market Outperform
Price Target: $19 → $18
Current: $10.21
Upside: +76.30%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Market Outperform
Price Target: $30 → $35
Current: $22.66
Upside: +54.46%
Halozyme Therapeutics
Aug 6, 2025
Maintains: Market Outperform
Price Target: $91 → $78
Current: $64.55
Upside: +20.84%